Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by KayakerBCon Jul 06, 2016 11:23am
112 Views
Post# 25027439

RE:When is something material going to happen?

RE:When is something material going to happen?
Silly me, I'll assume those are sincere questions and not your usual FUD.

He says at 3:20 people have been asking him when is something material going to happen? It looks like with the 6-9 months evaluation period virtually complete he doesn't really know, in my opinion.

As I've already explained to you, it's 6-9 months for each pharma just for evaluation.  Add months to that to decide if/what to move forward, and months more to negotiate a deal.  Many will not move forward for a variety of reasons.

He doesn't control the internal decision making process at the pharmas.  And if he does know when "something material going to happen" he certainly can't tell to us until it happens.

Did Shire and Medimmune leave because they want human data?

If they want(ed) human data they have to first do a license agreement and do the trials themselves.

Why wasn't the Herceptin program addressed in the clip?

The focus of the video was on the BIO conference rather than a full update.  Look at the MD&A for info on the collaboration with Brigham and Women’s Hospital.
Bullboard Posts